Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Mar 11, 2021 12:07am
229 Views
Post# 32769844

RE:Found this on yahoo forum

RE:Found this on yahoo forum
YukonJezza wrote:
supposed letter from Dan to someone inquiring about ate covid drug. I don't believe it though A member of the CEO.CA chat group sent an email to Dan asking about Antibe's participation with COVID trials. Below is what the claimed response from Dan was to this email. "What a great questionthanks!! In fact, we are working in partnership with the Canadian government on Covid with our drugs (not ATB-346), and doing so with despatch. We have had some (very early) promising results and so are continuing this effort. Since it is very early, we do not consider this to be material news; hence why I feel I can tell youif the results continue to be promising, at some point we would say this to the market. Since, however, it is not 346, we would decline to participate in the trial you mention. Thanks again for the great question, Best, Dan


Ya - I'm sure there's some truth to it ... if not all of it.
We know they are running trials with a drug of ours and I would have bet it was 340.
Then again, don't count 352 but that doesn't really make sense to me.
Get the blood thinning quality of Aspirin and the healing effects of H2S - in a safer med ... Bob's your uncle.
The wording is exactly as I'd expect from Dan.
What would really be a treat is 340 revamped in a new molecule (as Dan said they were going to investigate it, and all of a sudden, ended up working on IBD ????  ).
Maybe there is more to the story and they actually did start with a new molecule for 340 first.
I guess we have to wait and see.

It's all about creating value for the family of drugs IMO - leave nothing on the table ... therefore, take as much time as you need to show the value to potential Big Pharma partners.

Fingers crossed.
<< Previous
Bullboard Posts
Next >>